Another pathogenic mutation identified a few years later was a gain of function mutation of MYD88, an adaptor protein that mediates toll and interleukin (IL)-1 receptor signaling and activates NFκB pathway in distinct lymphoma subtypes. The gene discussed is NFKB1; the disease is lymphoma.